Serum Levels of Anti-Citrullinated Protein Antibody (ACPA) and TWEAK in Patients with Rheumatoid Arthritis: Association with Disease Activity and Treatment Modalities

Karkucak, Murat

doi:10.5606/tjr.2011.032

Cited by 2 publications

(4 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…24 Park et al 13 found a correlation between significantly increased sTWEAK levels and disease activity in RA patients. In contrast, unlike other studies, the research by Karkucak et al 12 showed no significant difference in the serum TWEAK levels of RA patients and healthy controls; this finding was attributed to the fact that about 50% of the RA patients in this study were receiving TNF blocker therapy, a type of therapy known to lower sTWEAK levels. Park et al 13 demonstrated that sTWEAK levels significantly reduce following TNF blocker therapy in RA patients.…”

Section: Discussioncontrasting

confidence: 99%

“…11 Few studies that have assessed the sTWEAK levels in RA have reported varying results. [12][13][14] Fetuin-A (Alpha 2-HS glycoprotein [g/L]) may qualify as a novel marker for the early detection of atherosclerosis. Recent data support the theory that the fatty liver/fetuin-A pathway plays an important role in regulating insulin sensitivity and may influence atherosclerosis in humans.…”

mentioning

confidence: 99%

See 1 more Smart Citation

The Evaluation of Serum Tumor Necrosis Factor-Like Weak Inducer of Apoptosis, Interleukin-6, Fetuin-A, Homeostatic Model Assessment-Insulin Resistance, and Insulin Levels in Rheumatoid Arthritis Patients in Clinical Remission

et al. 2019

View full text Add to dashboard Cite

Objectives: This study aims to examine the relationship of serum tumor necrosis factor-like weak inducer of apoptosis (sTWEAK) levels with interleukin (IL)-6, tumor necrosis factor-alpha (TNF-α), fetuin-A, insulin, homeostatic model assessment (HOMA)-insulin resistance (IR), and disease activity in patients with rheumatoid arthritis (RA) who are in remission or have low disease activity. Patients and methods: Fifty-four patients with RA (8 males, 46 females; mean age 52.7±12.3 years; range 40 to 64 years) and 34 healthy controls (6 males, 28 females; mean age 53.2±11.3 years; range 41 to 65 years) were included in the study. The sTWEAK, fetuin-A, insulin, lipid profile and IL-6 concentrations were determined. The HOMA-IR levels were calculated using a calculator. Disease activity score 28 was used to assess the disease activity. Results: The erythrocyte sedimentation rate, C-reactive protein, fetuin-A, and IL-6 levels were higher in the RA group than in the control group (p=0.004, 0.001, 0.001, and 0.003, respectively). sTWEAK levels were lower in the RA group than in the control group (p=0.007). There were no differences in the TNF-α, HOMA-IR, insulin, and lipid profile levels of the two groups (p>0.05). sTWEAK had a negative correlation with body mass index and fetuin-A (r=-0.261 and r=-0.287, respectively). Conclusion: We found that RA patients had lower sTWEAK levels and higher fetuin-A levels than the control group subjects. Furthermore, these two molecules were associated with each other. This study demonstrated that in RA patients, even if the disease is controlled with treatment, some molecules associated with an increased metabolic and cardiovascular risk continue to function. Follow-up studies on larger populations are warranted to confirm these findings.

show abstract

Section: Discussioncontrasting

confidence: 99%

mentioning

confidence: 99%

The Evaluation of Serum Tumor Necrosis Factor-Like Weak Inducer of Apoptosis, Interleukin-6, Fetuin-A, Homeostatic Model Assessment-Insulin Resistance, and Insulin Levels in Rheumatoid Arthritis Patients in Clinical Remission

et al. 2019

View full text Add to dashboard Cite

show abstract

“…The levels of serum ACPA were found to be statistically significantly higher in the RA cohorts (both RAPd and RA groups) as compared to the HC group. Importantly, high serum ACPA levels in those diagnosed with RA have been demonstrated in other studies [ 19 , 26 ], It is an established fact that ACPA are present in early RA disease and are highly specific for RA [ 27 ]. Biologically, ACPA have been shown to be involved in the inflammatory processes that occur in RA [ 28 , 29 ].…”

Section: Discussionmentioning

confidence: 83%

“…Sample size calculation was performed based on the mean levels and standard deviations (SD) of serum ACPA in RA group (86.0 ± 73.0 U/mL) and non-RA group (7.5 ± 7.4 U/mL) reported by Karkucak [ 19 ]. The required number of samples stands at 20 for each group in order to provide 80% power at a significance level of 5%.…”

Section: Methodsmentioning

confidence: 99%

Antibodies against citrullinated proteins in relation to periodontitis with or without rheumatoid arthritis: a cross-sectional study

et al. 2021

View full text Add to dashboard Cite

Background Previous studies have reported conflicting findings between serum anti-citrullinated protein antibodies (ACPA) levels in rheumatoid arthritis (RA) participants with and without periodontitis (Pd). This study aimed to analyse possible correlations between serum ACPA levels and clinical parameters in Pd and RA participants. Methods Full mouth periodontal examination (probing pocket depth, clinical attachment levels, gingival bleeding index, visual plaque index) was conducted and serum samples obtained from 80 participants comprising RA, Pd, both RA and Pd (RAPd) and healthy individuals (HC). Erythrocyte sedimentation rates (ESR) and periodontal inflamed surface area (PISA) were obtained. Serum samples were analysed for ACPA quantification using enzyme-linked immunosorbent assay (ELISA). Results Median levels (IU/mL) of ACPA (interquartile range, IQR) in RAPd, RA, Pd and HC groups were 118.58(274.51), 102.02(252.89), 78.48(132.6) and 51.67(91.31) respectively. ACPA levels were significantly higher in RAPd and RA as compared to HC group (p < 0.05). However, ACPA levels of any of the groups were not correlated with any clinical periodontal and RA parameters within the respective groups. Conclusions At individual level, the amount of serum ACPA seem to have an increasing trend with the diseased condition in the order of RAPd > RA > Pd > HC. However, lack of any significant correlation between the serum ACPA levels with the clinical Pd and RA parameters warrants further studies to investigate the causal link between RA and Pd for such a trend. Further studies involving more inflammatory biomarkers might be useful to establish the causal link between Pd in the development and progression of RA or vice versa.

show abstract

Serum Levels of Anti-Citrullinated Protein Antibody (ACPA) and TWEAK in Patients with Rheumatoid Arthritis: Association with Disease Activity and Treatment Modalities

Cited by 2 publications

References 12 publications

The Evaluation of Serum Tumor Necrosis Factor-Like Weak Inducer of Apoptosis, Interleukin-6, Fetuin-A, Homeostatic Model Assessment-Insulin Resistance, and Insulin Levels in Rheumatoid Arthritis Patients in Clinical Remission

The Evaluation of Serum Tumor Necrosis Factor-Like Weak Inducer of Apoptosis, Interleukin-6, Fetuin-A, Homeostatic Model Assessment-Insulin Resistance, and Insulin Levels in Rheumatoid Arthritis Patients in Clinical Remission

Antibodies against citrullinated proteins in relation to periodontitis with or without rheumatoid arthritis: a cross-sectional study

Contact Info

Product

Resources

About